GUCY2C

Across TCGA pan-cancer cohorts, GUCY2C Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GUCY2C data layer compared with 22 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher GUCY2C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GUCY2C expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SCLC, BRCA, and GBM are the cancer types where GUCY2C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
BRCA	DFS	Median	All	0.140	1.000	.001	17	view →
GBM	OS	Median	All	0.058	0.416	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.743	0.935	.012	6	view →
SKCM	OS	Median	II,III,IV	0.935	0.822	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GUCY2C–SCLC (OS)

Open the SCLC breakdown →